Hypertension-induced pathological cardiac hypertrophy (hypertensive heart) and exercise training-induced physiological cardiac hypertrophy (athletic heart) have differences in cardiac properties. We hypothesized that gene expression of energy metabolic enzymes differs between these two types of cardiac hypertrophy. 
Introduction
Pressure overload to the heart, such as hypertension, results in pathological cardiac hypertrophy (1, 2) . Pathological cardiac hypertrophy induces a reduction of cardiac function (1) . Furthermore, it has been reported that the progression of pathological cardiac hypertrophy results in heart failure (2) (3) (4) . On the other hand, exercise training causes cardiac hypertrophy, which is defined as the athletic heart (5, 6) . The athletic heart is a physiological cardiac hypertrophy which is induced a beneficial adaptive response in the cardiovascular system; decreased resting heart rate, decreased submaximal heart rate during exercise, and increased filling time and venous return (1, (7) (8) (9) . These adaptations can help to satisfy the increased cardiac demands during exercise, and maintain and/or enhance cardiac function in the resting condition (1, (7) (8) (9) . Therefore, the athletic heart demonstrates a beneficial adaptation in the cardiovascular system. Indeed, the progression of cardiac hypertrophy of the athletic heart does not cause heart failure. Thus, there are differences in cardiac properties between pathological cardiac hypertrophy, i.e., the hypertensive heart, and exercise training-induced physiological cardiac hypertrophy, although these two types of heart exhibit similar levels of cardiac hypertrophy.
The heart is known for its ability to produce energy from fatty acids (FA) because of its important β-oxidation apparatus, but it can also derive energy from several other substrates including glucose and lactate (10, 11) . In the heart in a physiological condition, FA is considered to account for 60-70% of oxygen consumption for energy production (11) . In FA metabolism, long-chain FA is important substrates for energy production in the heart (12) . However, pathological cardiac hypertrophy causes a breakdown of the balance of the energy metabolic system in the heart. It has been reported that glycolytic energy metabolism is accelerated in hypertensive cardiac hypertrophy induced by pressure overload due to aortic banding or pulmonary hypertension (13) (14) (15) (16) . Furthermore, it has also been demonstrated that the energy production in hypertensive cardiac hypertrophy in spontaneously hypertensive rats (SHR), which is a model of hypertension-induced pathological cardiac hypertrophy, showed a shift from the use of FA toward the use of glucose (17) . Thus, it is considered that SHR results in an abnormal balance of energy metabolic system in the heart. However, the adaptive response in the energy metabolic system in the physiological cardiac hypertrophy (exercise training induced-cardiac hypertrophy) is unclear.
Because there are differences in cardiac properties between the pathological cardiac hypertrophy and the physiological cardiac hypertrophy, we hypothesized that the gene expression of energy metabolic enzymes differs between these two types of cardiac hypertrophy, and this difference in molecular regulation of the energy metabolic system participates in the differences in cardiac properties. Therefore, we investigated the gene expression of key enzymes in the longchain FA, glucose, and lactic acid metabolic pathways in the hypertensive heart and the athletic heart in the rat. We also investigated whether cardiac function differs between these two types of cardiac hypertrophy. In the present study, we used SHR (SHR group; 19 weeks old) as a model of the hypertensive heart and swim-trained rats (Trained group; 19 weeks old, swimming training for 15 weeks, 5 days/week) as a model of the athletic heart.
Methods

Animals and Protocol
The experimental protocols were approved by the Committee on Animal Research at the University of Tsukuba. Male 4-week-old Wistar-Kyoto (WKY) rats and SHR were obtained from Charles River Japan Inc. (Yokohama, Japan) and cared for according to "The Guiding Principles for the Care and Use of Animals" based on the Helsinki Declaration of 1964. These rats were maintained on a 12:12-h light-dark cycle and received food and water ad libitum. Eight WKY rats were exercised by swimming for 5 days/week (Trained group), in a tank of water at 30-32 ºC with a surface area of 1,960 cm 2 and a depth of 50 cm. The rats swam for 5 min/day for the first 2 days, and then the swimming time was increased gradually over the 2-week period from 5 min/day to 75 min/day. Thereafter, the Trained group continued swimming training for 13 weeks. Therefore, the Trained group received 15 weeks of swimming training. Eight SHR (SHR group) and seven WKY rats (Control group) remained confined to their cages, but were handled daily. After swimming training for 15 weeks, the body weight and hemodynamic parameters of the animals were measured, and the heart was removed, weighed, and frozen in liquid nitrogen. Heart samples (left ventricle) were stored at 80 ºC for determination of the expression levels of mRNA of key enzymes of energy metabolic pathways by reverse transcription (RT)-polymerase chain reaction (PCR) analysis. Control rats and SHR were killed at the same time point as the Trained rats (Control: 19 weeks old, SHR: 19 weeks old, Trained: 19 weeks old).
We measured the mRNA expression of key enzymes in energy production from long-chain FA metabolism, glucose metabolism, and lactic acid metabolism in the heart as follows. Long-chain FA metabolic pathway: CD36 plays an important role as a long-chain FA-binding/transport protein from the extracellular compartment to the cytoplasm (18) . Acyl CoA synthase (ACoAS), carnitine palmitoyl transferase-I (CPT-I), and carnitine palmitoyl transferase-II (CPT-II) are the key regulatory enzymes in the FA metabolic pathway (19) (20) (21) . Isocitrate dehydrogenase (ISCD) is the key regulatory enzyme of the TCA cycle in the oxidative metabolic pathway (22) . Glucose metabolic pathway: Phosphofructokinase (PFK) is the key regulatory enzyme of the glucose metabolic pathway (23) . Lactic acid metabolic pathway: Lactate dehydrogenase (LDH) is the key regulatory enzyme of the lactic acid metabolic pathway (24) . Glycolytic metabolism is composed of glucose metabolism and lactic acid metabolism.
Hemodynamic Measurement and Tissue Sampling
On the day of the experiment, hemodynamic parameters were measured in anesthetized rats as described in our previous papers (25) (26) (27) (28) with minor modifications. The rats were anesthetized with sodium thiobutabarbital (50 mg/kg body weight i.p.). After the rats were fully sedated, arterial blood pressure and heart rate (HR) were measured via a cannula in the carotid artery, with a pressure transducer (model DX-360, Nihon Kohden, Tokyo, Japan) connected to a polygraph system (amplifier, AP-601G, Nihon Kohden; Tachometer, AT-601G, Nihon Kohden; thermal-pen recorder, WT-687G, Nihon Kohden). Stroke volume was measured by the thermodilution technique using a Cardiotherm 500 cardiac output computer (Columbus Instruments, Columbus, USA) equipped with a small animal interface (29, 30) . The thermistor microprobe catheter (Fr-1; Columbus Instruments) was inserted into the right carotid artery and advanced to the aortic arch. A catheter placed in the left jugular vein was advanced to the right ventricle for rapid bolus injection of 200 µl (plus catheter dead space) of cold saline. The saline solution was injected with a Hamilton constant rate syringe to ensure rapid and repeatable injections of the saline indicator solution. Arterial blood pressure and HR were monitored continuously. The cardiac output measurement repeated five times. Cardiac output was measured again when the aortic blood temperature of the rat was ≥36 ºC and the arterial blood pressure returned to the baseline value. Catheter placement was verified by postmortem examination. Stroke volume was determined by dividing cardiac output by the HR. After hemodynamic measurement, the whole heart was rapidly excised and washed thoroughly with cold saline to remove contaminating blood, then the left ventricle was separated from the right ventricle and atria.
RT-PCR to Determine Levels of mRNA Expression in Heart
Expression of CD36 mRNA, ACoAS mRNA, CPT-I mRNA, CPT-II mRNA, ISCD mRNA, PFK mRNA, and LDH mRNA in the left ventricle was analyzed by RT-PCR. Expression of β-actin mRNA was determined as an internal control. Semiquantitative RT-PCR was performed according to the method described in our previous papers (26, (31) (32) (33) (34) .
Total tissue RNA was isolated by acid guanidinium thiocyanate-phenol-chloroform extraction with Isogen (Nippon Gene, Toyama, Japan). Briefly, the tissue was homogenized in Isogen (100 mg tissue/ml Isogen) with a Polytron tissue homogenizer (model PT10SK/35, Kinematica, Lucerne, Switzerland). The precipitated RNA was extracted with chloroform, precipitated with isopropanol, and washed with 75% (vol/vol) ethanol. The resulting RNA was resolved in diethyl pyrocarbonate-treated water, treated with DNase I (Takara, Shiga, Japan), and extracted again with Isogen to eliminate the genomic DNA. The RNA concentration was determined spectrophotometrically at 260 nm.
Total tissue RNA (10 µg) was primed with 0.05 µg of oligo d(pT)12-18 and reverse transcribed by avian myeloblastosis virus RT using a first-strand cDNA synthesis kit (Life Sciences, Petersburg, USA). The reaction was performed at 43 ºC for 60 min.
The cDNA was diluted in a 1:10 ratio, and 1 µl was used for PCR. Each PCR reaction contained 10 mmol/l Tris-HCl (pH 8. The amplified PCR products were electrophoresed on 1.2% agarose gels, stained with ethidium bromide, visualized by an ultraviolet transilluminator, and photographed. The photographs were scanned by CanoScan 600 (Canon, Tokyo, Japan), and quantification was performed by a computer with MacBAS software (Fuji Film, Tokyo, Japan) according to the method described in our previous papers (26, (31) (32) (33) (34) .
Statistical Analysis
Values are expressed as means SEM. Statistical analysis was carried out by analysis of variance followed by Scheffé's F-test for multiple comparisons. P 0.05 was accepted as significant.
Results
Body weight was significantly lower in the Trained group (338.8 4.4 g) than the Control (391.7 5.8 g; p 0.05) and SHR (379.0 6.9 g; p 0.05) groups. There was no significant difference in body weight between the Control and SHR groups. Left ventricular mass index for body weight (LVW/BW) was significantly higher in the SHR and Trained groups than the Control group (Fig. 1A) . There was no significant difference in LVW/BW between the SHR and Trained groups (Fig. 1A) . Resting heart rate was significantly lower in the Trained group than the Control and SHR groups, and that in the SHR group was significantly higher than that in the Control group (Fig. 1B) . Systolic and diastolic blood pressure were significantly higher in the SHR group than the Control and Trained groups (Fig. 1C and D) .
There was no significant difference in systolic or diastolic blood pressure between the Control and Trained groups. Stroke volume was lower in the SHR group than the Trained and Control groups (Fig. 1E) .
The mRNA expression of CD36, which is involved in the uptake of long-chain FA, in the heart was almost never detected in the SHR group (Fig. 2) . However, expression of CD36 mRNA was detected in the hearts of the Trained and Control groups, and there was no significant difference between the two groups (Fig. 2) .
The mRNA expression of ACoAS, CPT-I, CPT-II, and ISCD, which are key regulatory enzymes in the long-chain FA metabolic pathway, in the heart was significantly higher in the SHR group than in the Control group (Fig. 3A-D) . The mRNA expression of CPT-I and ISCD in the heart was significantly higher in the SHR group than in the Trained group (Fig. 3B and D ). There were no significant differences between the Control and Trained groups in the expression of ACoAS, CPT-I, and ISCD mRNA (Fig. 3A, B, and D) . On the other hand, the expression of CPT-II mRNA in the heart was significantly higher in the Trained group than in the Control group (Fig. 3C) .
The mRNA expression of PFK, which is a key regulatory enzyme in glucose metabolism, in the heart was markedly higher
Fig. 1. Left ventricular weight to body weight ratio (LVW/BW; A), resting heart rate (B), systolic blood pressure (SBP; C), diastolic blood pressure (DBP; D), and stroke volume (E) in Control rats (n 7), SHR (n 8), and Trained rats (n 8, swim training for 15 weeks). Data are expressed as means and SEM.
in the SHR group than the Control and Trained groups (Fig. 4) . There was no significant difference in the expression of PFK mRNA between the Control and Trained groups (Fig. 4) .
The mRNA expression of LDH, which is a key regulatory enzyme in lactic acid metabolism, in the heart was significantly higher in the SHR group than the Control and Trained groups (Fig. 5) . There was no significant difference in the expression of LDH mRNA between the Control and Trained groups (Fig. 5) .
Discussion
We demonstrated for the first time that the manner of mRNA expression of key enzymes in energy metabolic pathway (long-chain FA, glucose, and lactic acid) in the heart differed in pathological cardiac hypertrophy which is induced by hypertension, and physiological cardiac hypertrophy which is induced by exercise training. In the present study, the hearts of SHR and Trained rats developed cardiac hypertrophy, as evidenced by an increase in LVW/BW. SHR showed a decline of cardiac function, i.e., decrease in stroke volume. On the other hand, Trained rats developed cardiac hypertrophy with enhancement of cardiac function, i.e., increase in stroke volume. The Trained rats represented a decrease in resting heart rate, and these data suggested that the Trained rats exhibited an athletic heart (physiological cardiac hypertrophy). Therefore, these results suggest that the SHR exhibited pathological cardiac hypertrophy and Trained rats exhibited physiological cardiac hypertrophy (athletic heart). We consider that the molecular regulation in the energy metabolic system differed in pathological cardiac hypertrophy and physiological cardiac hypertrophy, and these differences may participate in the greater differences in cardiac function.
The present study demonstrated that the hearts of SHR and Trained rats developed cardiac hypertrophy. In the present study, however, the manner of mRNA expression of key enzymes in the long-chain FA, glucose, and lactic acid metabolic pathways in the heart and cardiac function differed in the SHR and Trained rats. These results suggest that the regulatory system of gene expression of energy metabolic pathways in the heart differed in hypertension induced-pathological cardiac hypertrophy which causes a decline of cardiac function, and exercise training induced-physiological cardiac hypertrophy which causes enhancement of cardiac function, although both types of hearts exhibit similar degree of cardiac hypertrophy. Therefore, it is considered that the hypertrophied heart of Trained rats causes a normal molecular regulation which maintains a normal balance of the energy metabolic system, whereas the hypertrophied heart of SHR causes an abnormal molecular regulation which shows a breakdown of the balance of the FA metabolic system and up-regulation of the glycolytic metabolic system. The physiological cardiac hypertrophy shows enhancement of cardiac function at rest and during exercise and is not a risk factor for heart failure. On the other hand, the progression of pathological cardiac hypertrophy results in heart failure (2-4), and the failing heart causes a breakdown of molecular regulatory system of energy metabolism (15) . Taken together, the alteration of energy metabolic system in the heart may affect cardiac function and viability of heart, because myocardial contraction involves continuative supply of energy. Therefore, we consider that differences in the manner of gene expression of the energy metabolic system between the pathological cardiac hypertrophy and the physiological cardiac hypertrophy may be one of the causal factors for the difference in hemodynamic features and the prognosis of cardiac hypertrophy. Thus, the balance of molecular phenotypes in myocardial energy metabolic system may utilize as a molecular marker which indicates normal or abnormal adaptations of the cardiac function and prognosis of cardiac hypertrophy.
CD36, a membrane protein that is implicated in the binding and transport of long-chain FA, is expressed in cardiac myocytes (36, 37) . Recent studies have identified a deletion in the SHR for CD36 in adipose tissue, cardiac muscle, and skeletal muscle (18) . The deletion of CD36 in the SHR re- sults in the near-complete lack of expression of normal CD36 protein (18) . The present study also showed that mRNA expression of CD36 was almost never detected in the heart of SHR. Our data is in accordance with this report (18) . It has been reported that the uptake of 125 I-β-methyl-piodophenyl-pentadecanoic acid (BMIPP; an index of longchain FA metabolism), using a cardiac radionuclide imaging method, in the heart of SHR was significantly reduced compared with that in normotensive rats (38) . It has also been reported that type I CD36 deficiency patients show decreased myocardial uptake of BMIPP and increased myocardial uptake of 18 F-fluorodeoxyglucose (an index of glucose metabo- lism) (39, 40) . Furthermore, it has been demonstrated that CD36 knockout mice show reduced uptake and utilization of long-chain FA in the heart (41) . Taken together, these findings suggest that, in the heart of SHR, the deletion of CD36 gene causes a decrease in FA uptake and utilization. The present study showed that mRNA expression of CD36 was almost never detected in the heart of SHR, whereas mRNA expression of ACoAS, CPT-I, CPT-II, and ISCD in the longchain FA metabolic pathway was significantly higher in the heart of SHR compared with Control rats. On the basis of the results from past studies and the present investigation, it is possible that dysfunction of CD36 in the heart of SHR causes a decrease in the uptake of long-chain FA, and its dysfunction induces a decrease in long-chain FA storage in myocytes, thereby resulting in compensatory up-regulation of gene transcription of the myocardial long-chain FA metabolic enzymes downstream of CD36. Furthermore, in the present study, mRNA expression of PFK and LDH in the glycolytic metabolic pathway in the heart was markedly higher in SHR compared with Control and Trained rats. These results indicate that the hypertrophied heart of SHR induces up-regulation of gene expression of the glycolytic metabolic pathway. It is well known that hypertensive-induced cardiac hypertrophy in SHR causes a decrease in myocardial capillary density with development of cardiac hypertrophy, suggesting that the myocardium of SHR reduces supply of oxygen (42, 43) . Taken together, the glycolytic metabolic system in the heart of SHR may cause compensatory up-regulation against the decrease in energy production from FA metabolism induced by both of dysfunction of CD36 and decrease in supply of oxygen. In this regard, Christe et al. (17) demonstrated to cause a shift from the use of FA toward the use of glucose in the perfused heart of SHR. Therefore, it is considered that the pathological cardiac hypertrophy of SHR exhibits an abnormal energy metabolism which causes a breakdown of molecular regulation of energy metabolic system by both of myocardial CD36 dysfunction and cardiac hypertrophy with relative decrease in supply of oxygen.
Fig. 2. Expression of CD36 mRNA in the heart (left ventricle) of Control rats (n 7), SHR (n 8), and Trained rats (n 8). Typical examples of reverse transcription (RT)-polymerase chain reaction (PCR) analysis are shown for the levels of CD36 mRNA and β-actin mRNA (upper). We determined the expression of β-actin
Fig. 3. Expression of acyl CoA synthase (ACoAS) mRNA (A), carnitine palmitoyl transferase-I (CPT-I) mRNA (B), carnitine palmitoyl transferase-II (CPT-II) mRNA (C), and isocitrate dehydrogenase (ISCD) mRNA (D) in the heart (left ventricle) of Control rats (n 7), SHR (n 8), and Trained rats (n 8). Typical examples of reverse transcription (RT)-polymerase chain reaction (PCR) analysis are shown for the levels of ACoAS mRNA (A: upper), CPT-I mRNA (B: upper), CPT-II mRNA (C: upper), ISCD mRNA (D: upper) and β-actin mRNA (A-D: upper). We determined the expression of β-actin mRNA as an internal control. Each lower figure shows the results of the statistical analysis of the levels of expression of ACoAS mRNA (A), CPT-I mRNA (B), CPT-II mRNA (C), and ISCD mRNA (D) by a densitometer. Photos of PCR products
Fig. 5. Expression of lactate dehydrogenase (LDH) mRNA in the heart (left ventricle) of Control rats (n 7), SHR (n 8), and Trained rats (n 8). Typical examples of reverse transcription (RT)-polymerase chain reaction (PCR) analy-
Fig. 4. Expression of phosphofructokinase (PFK) mRNA in the heart (left ventricle) of Control rats (n 7), SHR (n 8), and Trained rats (n 8). Typical examples of reverse transcription (RT)-polymerase chain reaction (PCR) analysis
The main energy production in the heart is provided by FA metabolism (11) . The present study demonstrated that the expression of CPT-II mRNA in the heart was significantly higher in Trained rats compared with Control rats. CPT-II is involved in the transfer of long-chain FA into the mitochondrial matrix (44) , and changes in the mRNA expression and activity of CPT-II affect FA metabolism (45, 46) . Furthermore, it has been reported that the increase in mRNA expression of CPT II in the skeletal muscle was induced by exercise training with increased contractile activity in the skeletal muscle (47) . Therefore, it is possible that the increase of CPT-II mRNA expression in the Trained rat heart (exercise training induced-cardiac hypertrophy) results in a beneficial regulation for energy production efficiency from FA metabolism. Furthermore, the present study showed that the mRNA expression of ACoAS, CPT-I, ISCD, and CD36 in the long-chain FA metabolic pathway maintained a normal state in the heart of Trained rats. Therefore, the exercise training induced-cardiac hypertrophy may exhibit a normal energy metabolism and maintain and/or up-regulate a molecular regulation of energy metabolic system in the heart. The present study also showed that the mRNA expression of PFK and LDH in the glycolytic metabolic pathway did not change in the exercise training induced-cardiac hypertrophy. It has been reported that exercise training caused angiogenesis in the heart with development of physiological cardiac hypertrophy and maintained and/or increased in myocardial capillary density, suggesting that exercise training-induced physiological cardiac hypertrophy results in maintenance and/or up-regulation of supply of oxygen in the heart (48) (49) (50) . On the basis of the results from past studies and the present investigation, it is possible that the glycolytic metabolic system in exercise training-induced cardiac hypertrophy did not cause a compensatory up-regulation against cardiac hypertrophy, because exercise training maintains and/or up-regulates not only molecular regulation of energy metabolic system in the heart, but also supply of oxygen in the heart, e.g., maintenance and/or up-regulation of aerobic energy metabolic system in the heart.
In conclusion, we demonstrated that the manner of mRNA expression of key enzymes in the long-chain FA, glucose, and lactic acid metabolic pathways in the heart differed in the pathological cardiac hypertrophy (hypertensive heart) and physiological cardiac hypertrophy (athletic heart). These results suggest that the regulatory system of gene expression of the energy metabolic pathway differs in pathological cardiac hypertrophy and physiological cardiac hypertrophy. The present study also showed that cardiac function differed in pathological cardiac hypertrophy and physiological cardiac hypertrophy. Therefore, we consider that the molecular regulation in the energy metabolic system differed in pathological cardiac hypertrophy which is induced by hypertension, and physiological cardiac hypertrophy which is induced by exercise training, and these differences may participates in the differences in cardiac properties, such as cardiac function and the prognosis of cardiac hypertrophy.
